Compare YSXT & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | NEPH |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 39.0M |
| IPO Year | 2023 | 2004 |
| Metric | YSXT | NEPH |
|---|---|---|
| Price | $1.45 | $3.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 5.6K | ★ 41.9K |
| Earning Date | 07-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $17.81 |
| Revenue Next Year | N/A | $15.90 |
| P/E Ratio | ★ $5.57 | $29.63 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.50 | $2.66 |
| 52 Week High | $3.14 | $6.42 |
| Indicator | YSXT | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 46.29 |
| Support Level | $1.21 | $3.15 |
| Resistance Level | $1.51 | $3.78 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 35.71 | 77.08 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.